Thomas Dirschka
Research Subjects
Thomas Dirschka has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Claus Oster-Schmidt
10 shared publicationsRoland Hartwig
6 shared publicationsErhard Bierhoff
Heinz-Werner-Seifert-Institut für Dermatopathologie, Bonn
5 shared publicationsHagen Tronnier
Dermatologische Praxis Dr. Thomas Dirschka, Wuppertal
3 shared publications- Uwe Reinhold
MVZ Dermatologisches Zentrum Bonn GmbH, Bonn, Deutschland
3 shared publications - Claus Garbe
Centre for Dermatooncology, Department of Dermatology Eberhard Karls University Tuebingen Germany
2 shared publications
Latest Publications
- 24 November 2013
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 11 (12) , 1194-1196
Alitretinoin: eine effektive Therapieoption der pagetoiden Retikulose
- 24 November 2013
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 11 (12) , 1194-1196
Alitretinoin: eine effektive Therapieoption der pagetoiden Retikulose
- 2 August 2013
- Published by Wiley in British Journal of Dermatology
- Vol. 169 (5) , 1156-1157
Follow-up analysis of the efficacy of photodynamic therapy in actinic keratosis: reply from the authors
- 2 August 2013
- Published by Wiley in British Journal of Dermatology
- Vol. 169 (5) , 1156-1157
Follow-up analysis of the efficacy of photodynamic therapy in actinic keratosis: reply from the authors
- 23 July 2013
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 11 (12) , 1194-1195
Alitretinoin: an effective treatment option for pagetoid reticulosis
- 23 July 2013
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 11 (12) , 1194-1195
Alitretinoin: an effective treatment option for pagetoid reticulosis
- 1 March 2011
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 36 (2) , 149-154
An open-label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids
Summary: Background. Blinded, controlled studies have found that oral alitretinoin is well tolerated and effective in the treatment of severe chronic hand eczema (CHE). Aim. To assess the safety and efficacy of oral alitretinoin in patients with severe CHE in an open-label study using flexible dosing and a new measurement of patient-relevant benefits. Methods. In total, 249 patients aged 18–75 years with severe CHE unresponsive to treatment with topical corticosteroids received alitretinoin 30 mg once daily for up to 24 weeks. Safety assessments included adverse events (AEs) and laboratory tests. Efficacy assessments included Physician’s Global Assessment (PGA), the Modified Total Lesion Symptom Score, Patient’s Global Assessment and extent of disease, as well as intensity of pain and pruritus as determined by visual analogue scale (VAS) and a categorical scale for pruritus. Results. Alitretinoin was well tolerated when given for up to 24 weeks. Dose reduction occurred in 16.5% of patients. Dose interruption was required for 15.7% of patients, most commonly for headache. AEs and laboratory changes comprised effects typical of the retinoid class. A PGA response of ‘clear’ or ‘almost clear’ hands was reported for 46.6% of patients, similar to the response rate seen in blinded trials. Results of VAS and categorical assessments of pruritus provided supporting evidence of efficacy, and treatment was assessed as providing meaningful benefits to patients. Conclusions. Oral alitretinoin 30 mg was well tolerated and effective, and provided distinct therapeutic benefits in severe CHE, as assessed by patients.
- 1 March 2011
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 36 (2) , 149-154
An open-label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids
Summary: Background. Blinded, controlled studies have found that oral alitretinoin is well tolerated and effective in the treatment of severe chronic hand eczema (CHE). Aim. To assess the safety and efficacy of oral alitretinoin in patients with severe CHE in an open-label study using flexible dosing and a new measurement of patient-relevant benefits. Methods. In total, 249 patients aged 18–75 years with severe CHE unresponsive to treatment with topical corticosteroids received alitretinoin 30 mg once daily for up to 24 weeks. Safety assessments included adverse events (AEs) and laboratory tests. Efficacy assessments included Physician’s Global Assessment (PGA), the Modified Total Lesion Symptom Score, Patient’s Global Assessment and extent of disease, as well as intensity of pain and pruritus as determined by visual analogue scale (VAS) and a categorical scale for pruritus. Results. Alitretinoin was well tolerated when given for up to 24 weeks. Dose reduction occurred in 16.5% of patients. Dose interruption was required for 15.7% of patients, most commonly for headache. AEs and laboratory changes comprised effects typical of the retinoid class. A PGA response of ‘clear’ or ‘almost clear’ hands was reported for 46.6% of patients, similar to the response rate seen in blinded trials. Results of VAS and categorical assessments of pruritus provided supporting evidence of efficacy, and treatment was assessed as providing meaningful benefits to patients. Conclusions. Oral alitretinoin 30 mg was well tolerated and effective, and provided distinct therapeutic benefits in severe CHE, as assessed by patients.
- 1 January 2011
- Published by Elsevier
- p. 901-951
Therapieprinzipien
- 1 January 2011
- Published by Elsevier
- p. 671-725
Erkrankungen der Hautanhangsgebilde
- 1 January 2011
- Published by Elsevier
- p. 615-626
Lichen planus, Prurigoerkrankungen
- 1 January 2011
- Published by Elsevier
- p. 227-340
Erregerbedingte Hauterkrankungen
- 1 January 2011
- Published by Elsevier
- p. 51-102
Häufige Leitsymptome und ihre Differenzialdiagnosen
- 1 January 2011
- Published by Elsevier
- p. 13-50
Arbeitstechniken und diagnostische Verfahren